IL-38, a potential therapeutic agent for lupus, inhibits lupus progression

Wang-Dong Xu,Lin-Chong Su,Lu Fu,You-Yu Lan,Xiao-Yan Liu,Qi Huang,Qian Wu,Jie Zhou,An-Fang Huang
DOI: https://doi.org/10.1007/s00011-022-01581-3
IF: 6.986
2022-07-02
Inflammation Research
Abstract:Previous studies reported that IL-38 was abnormally expressed in patients with systemic lupus erythematosus (SLE). However, the involvement of IL-38 in the pathophysiology of SLE remains unknown.
immunology,cell biology
What problem does this paper attempt to address?